Third tier: 7.5 mg (weeks 9-12) At 10 mg/mL, 7.5 mg requires 75 units
Side effects remain a key concern, with real-world data showing 43.5% of users reporting at least one adverse effect, including nausea in 36.9%, fatigue in 16.7%, and vomiting in 16.3% of cases
any adjustments to escalation schedules would be protocol-specific and determined by the trial clinician, as established dose-modification data for retatrutide are not yet available
For more vial-specific guidance, the compounded tirzepatide dosage chart explores pharmacy-specific considerations in more detail
Customers comparing supplier options can also view Retatrutide Supplier UK, which explains what research buyers may consider when reviewing UK peptide suppliers
Injection site reactions are typically mild and tend to decrease over time